CytomX Therapeutics stock trades ahead of November 5 results

Published on 10/15/2026 at 19:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue was USD 1.42 million for June 30, 2026. CytomX Therapeutics stock costs EUR 2.13 on October 15, 2026.

Clinical calendar and finances

MarketBeat estimated November 5, 2026 as CytomX's next results date.
Revenue totaled USD 1.42 million for the quarter ended June 30, 2026.
CytomX Therapeutics stock costs EUR 2.13 at Lang & Schwarz on October 15, 2026 at 7:06 p.m. CEST.
Market capitalization stood at USD 521.9 million on October 15, 2026.

CTMX, US23284F1057, Illustration mit AI erstellt.

MarketBeat estimates that CytomX Therapeutics will report third-quarter 2026 results on November 5, 2026, before the market opens, according to its earnings page published October 10, 2026 and updated October 15, 2026. The date gives investors a defined near-term checkpoint for the clinical-stage biotech. CytomX Therapeutics stock was trading at EUR 2.13 at Lang & Schwarz on October 15, 2026 at 7:06 p.m. CEST.

Revenue fell in the second quarter

CytomX Therapeutics reported USD 1.42 million in revenue for the quarter ended June 30, 2026, down from USD 18.66 million in the same quarter of 2025. The company attributed the decline mainly to a completed collaboration obligation with Bristol Myers Squibb and lower research activity in its Astellas collaboration. Net loss was USD 20.67 million, or USD 0.09 per diluted share, for the second quarter of 2026.

Cash supports the clinical pipeline

The company ended June 30, 2026 with USD 330.3 million in cash, cash equivalents and investments, according to the same release. CytomX said the balance supported a cash runway at least into the second half of 2028, while its Varseta-M program had enrolled 113 patients across dose escalation, expansion and optimization phases.

The latest Nasdaq quote was USD 2.40 at 1:13 p.m. ET on October 15, 2026, compared with a previous close of USD 2.23. The stock's 52-week range was USD 2.20 to USD 8.21, and its market capitalization was USD 521.9 million. The price-to-earnings ratio was minus 5.32.

Valuation and November date

The November 5, 2026 reporting date is an estimate rather than a company-confirmed calendar entry. MarketBeat also lists expected third-quarter revenue of USD 10.38 million and adjusted earnings per share of minus USD 0.09, with both figures representing consensus estimates for that quarter.

Comparison with peers

CytomX (Nasdaq, USD): 7.40 percent, price-to-earnings ratio minus 5.32, market capitalization USD 521.9 million.

Amgen (Nasdaq, USD): 3.38 percent, price-to-earnings ratio 27.38, market capitalization USD 238.2 billion.

Bristol-Myers Squibb (NYSE, USD): 3.19 percent, price-to-earnings ratio 13.47, market capitalization USD 125.0 billion.

EUR quote after hours

CytomX is a clinical-stage biotechnology company developing conditionally activated cancer medicines through its Probody platform. Its current pipeline includes Varseta-M and CX-801, while collaborations with larger pharmaceutical companies remain an important part of its development model.

The further course of trading is shown by the continuously updated real-time quote of CytomX Therapeutics stock.